RIGL
RIGEL PHARMACEUTICALS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 20 ▼ 1 insider sell $145.4K at $36.36
- Apr 21 ▼ Rigel Pharmaceuticals announced that Eli Lilly has elected to termin…
- May 5 ▼ Rigel Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.44, mi…
- May 12 ▲ Rigel Pharmaceuticals entered into a worldwide exclusive license agr…
- May 26 ▼ 1 insider sell $72.9K at $29.17
- Jun 15 HSR Early Termination: Rigel Pharmaceuticals, Inc…
- Jun 22 ▼ 1 insider sell $87.5K at $35.00
- Aug 4 Rigel Pharmaceuticals reported Q2 2026 revenue of $78.7M (net produc…
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $305.9K.
- InstitutionsMIXED
Q3 2026: 22 added (1 new), 18 trimmed or exited. Largest new: Assenagon Asset Management S.A $25.8M.
- AnalystsBULLISH
8 of 11 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −7.2% to 2.54M shares. 12.9 days to cover, ≈13.5% of shares.
- TrendDOWNTREND
8% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | DOUBLED | $60.5M |
| AMERICAN CENTURY COMPANIES INC | ADD | $50.3M |
| Assenagon Asset Management S.A. | NEW | $25.8M |
| UBS Group AG | ADD | $8.5M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $4.8M |
| CREDIT AGRICOLE S A | DOUBLED | $3.8M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $3.5M |
| Nuveen, LLC | TRIM | $2.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analystsPrice is below the lowest target. Median implies +26%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | Citigroup MAINTAIN | Buy |
| Nov 6, 2026 | Cantor Fitzgerald MAINTAIN | Neutral |
| Oct 19, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 17, 2026 | Piper Sandler MAINTAIN | Neutral |
| Aug 14, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Jun 18, 2026 | Cantor Fitzgerald MAINTAIN | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Schorno Dean L EVP & Chief Financial Officer Sep 2, 2026 | EXERCISE | $8.8K |
Schorno Dean L EVP & Chief Financial Officer Sep 2, 2026 | EXERCISE | $48.4K |
Schorno Dean L EVP & Chief Financial Officer Sep 2, 2026 | EXERCISE | $11.6K |
Schorno Dean L EVP & Chief Financial Officer Sep 2, 2026 | EXERCISE | $31.1K |
Furey Raymond J. EVP, GC, CCO & Corp Sec Sep 1, 2026 | TAX W/H | $41.7K |
Santos David A EVP, Chief Commercial Officer Sep 1, 2026 | TAX W/H | $41.5K |
RODRIGUEZ RAUL R CEO, President Sep 1, 2026 | TAX W/H | $115.1K |
Schorno Dean L EVP & Chief Financial Officer Sep 1, 2026 | TAX W/H | $44.1K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
12 filings · 1 bullish · 3 bearish · 1 mixed · 7 neutral- NEUTRAL SC 13G/ANov 16, 2026
Armistice Capital LLC filed an amended Schedule 13G disclosing a 8.22% passive stake in Rigel Pharmaceuticals as of September 30, 2026, up from a prior filing (likely 0% or a smaller position). The filing confirms Armistice as a top holder alongside Morgan Stanley (6.5%) and State Street (4.7%)…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GNov 13, 2026
Morgan Stanley filed a Schedule 13G disclosing a 6.5% passive stake in Rigel Pharmaceuticals as of…
Monitor for any future 13D conversion or increased activism from Morgan Stanley, though the 13G certification indicates passive intent. The accumulation by a major financial institution adds to…
- NEUTRAL SC 13GNov 10, 2026
State Street Corporation filed a Schedule 13G disclosing a 4.7% passive stake in Rigel…
This is a routine passive disclosure by a large index/asset manager. No change in investment thesis. Monitor future 13F filings for position size changes and any 13D conversion by other holders.
- BEARISH 8-KNov 5, 2026
Rigel Pharmaceuticals reported Q3 2026 revenue of $80.9M (above $80.1M consensus) and GAAP EPS of…
The EPS miss and rising expense base (R&D + SG&A up 55% YoY) overshadow the VEPPANU launch. Monitor the Q4 2026 VEPPANU sales trajectory and the R289 Phase 2 dose selection by year-end for the next…
All RIGL filing & press-release reports (12)
- SC 13G/A reportNov 16, 2026
- SC 13G reportNov 13, 2026
- SC 13G reportNov 10, 2026
- 8-K reportNov 5, 2026
- 8-K reportAug 4, 2026
- 8-K reportJun 17, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 20, 2026
- 8-K reportMay 12, 2026
- 8-K reportMay 5, 2026
- 8-K reportApr 21, 2026
- DEFA14A reportApr 3, 2026